Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Fergenbaum J. Harms of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review. Toronto: Health Quality Ontario (HQO). Rapid Review. 2015 Authors' conclusions Based on the evidence, the following conclusions can be made:
There are major harms (unnecessary risks) associated with PSA screening, including:
• harms associated with prostate biopsy
• overdiagnosis
There are minor harms associated with PSA screening including:
• harms associated with PSA testing
PSA-based screening for prostate cancer results in harms related to the screening process, biopsy procedures, and, most significantly, the treatment of overdiagnosed cases. PSA-based screening of prostate cancer results in overdiagnosis and overtreatment without providing a mortality advantage, thereby exposing men to invasive treatments and potential complications. Consequently, PSA-based screening in prostate cancer results in more harm than benefit Indexing Status Subject indexing assigned by CRD MeSH Early Detection of Cancer; Humans; Male; Mass Screening /adverse effects; Prostate-Specific Antigen; Prostatic Neoplasms Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5 Email: EDSinfo@hqontario.ca AccessionNumber 32015000712 Date abstract record published 09/06/2015 |